ADAM9 and metastatic malignant neoplasm in the lymph nodes: Although we found no significant correlations between elevated ADAM9 expression levels and various clinicopathological features, such as Gleason scores, clinical T stages, pathological T stages, and lymph node metastasis, we observed a trend where tumor tissues with a clinical T4 stage exhibited higher ADAM9 expression compared to those with clinical T1-T3 stages (Figure 2B).